Skip to content 
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. more
| Time Frame | IBIO | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -8.26% | -1.08% | -1.38% |
| 1-Month Return | -12.6% | -0.47% | -1.81% |
| 3-Month Return | 93.04% | 2.13% | 1.38% |
| 6-Month Return | 204.11% | 17.04% | 5.68% |
| 1-Year Return | -38.33% | 6.56% | 11.74% |
| 3-Year Return | -88.32% | 16.78% | 65.15% |
| 5-Year Return | -99.81% | 34.34% | 73.68% |
| 10-Year Return | -99.92% | 137.88% | 260.03% |
| Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 2.37M | 1.88M | 50.00K | 225.00K | 400.00K | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":79.46,"profit":true},{"date":"2023-06-30","value":2.11,"profit":true},{"date":"2024-06-30","value":9.49,"profit":true},{"date":"2025-06-30","value":16.87,"profit":true}] |
| Cost of Revenue | 1.46M | 3.79M | 1.11M | 1.25M | - | [{"date":"2021-06-30","value":38.57,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":29.17,"profit":true},{"date":"2024-06-30","value":32.97,"profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Gross Profit | 909.00K | (1.91M) | 50.00K | 225.00K | 400.00K | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-209.79,"profit":false},{"date":"2023-06-30","value":5.5,"profit":true},{"date":"2024-06-30","value":24.75,"profit":true},{"date":"2025-06-30","value":44,"profit":true}] |
| Gross Margin | 38.34% | (101.22%) | 100.00% | 100.00% | 100.00% | [{"date":"2021-06-30","value":38.34,"profit":true},{"date":"2022-06-30","value":-101.22,"profit":false},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] |
| Operating Expenses | 32.02M | 27.79M | 29.34M | 16.86M | 19.00M | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":86.79,"profit":true},{"date":"2023-06-30","value":91.64,"profit":true},{"date":"2024-06-30","value":52.65,"profit":true},{"date":"2025-06-30","value":59.34,"profit":true}] |
| Operating Income | (31.11M) | (29.70M) | (29.31M) | (16.63M) | (18.60M) | [{"date":"2021-06-30","value":-3111100000,"profit":false},{"date":"2022-06-30","value":-2969700000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-1663400000,"profit":false},{"date":"2025-06-30","value":-1860200000,"profit":false}] |
| Total Non-Operating Income/Expense | 5.58M | (1.05M) | 32.00K | 1.38M | 450.00K | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-18.8,"profit":false},{"date":"2023-06-30","value":0.57,"profit":true},{"date":"2024-06-30","value":24.75,"profit":true},{"date":"2025-06-30","value":8.06,"profit":true}] |
| Pre-Tax Income | (23.21M) | (29.51M) | (29.31M) | (15.44M) | (18.38M) | [{"date":"2021-06-30","value":-2321300000,"profit":false},{"date":"2022-06-30","value":-2951300000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-1544300000,"profit":false},{"date":"2025-06-30","value":-1837700000,"profit":false}] |
| Income Taxes | 46.00K | 701.00K | (1.20M) | 9.64M | - | [{"date":"2021-06-30","value":0.48,"profit":true},{"date":"2022-06-30","value":7.27,"profit":true},{"date":"2023-06-30","value":-12.49,"profit":false},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Income After Taxes | (23.26M) | (30.21M) | (28.11M) | (25.08M) | - | [{"date":"2021-06-30","value":-2325900000,"profit":false},{"date":"2022-06-30","value":-3021400000,"profit":false},{"date":"2023-06-30","value":-2810700000,"profit":false},{"date":"2024-06-30","value":-2507900000,"profit":false},{"date":"2025-06-30","value":"-","profit":true}] |
| Income From Continuous Operations | (23.21M) | (50.30M) | (29.31M) | (15.44M) | (18.38M) | [{"date":"2021-06-30","value":-2321300000,"profit":false},{"date":"2022-06-30","value":-5030400000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-1544300000,"profit":false},{"date":"2025-06-30","value":-1837700000,"profit":false}] |
| Income From Discontinued Operations | (20.79M) | (20.79M) | (35.70M) | - | - | [{"date":"2021-06-30","value":-2079100000,"profit":false},{"date":"2022-06-30","value":-2079100000,"profit":false},{"date":"2023-06-30","value":-3569900000,"profit":false},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Net Income | (23.21M) | (50.39M) | (29.31M) | (24.91M) | (18.38M) | [{"date":"2021-06-30","value":-2320700000,"profit":false},{"date":"2022-06-30","value":-5039100000,"profit":false},{"date":"2023-06-30","value":-2931100000,"profit":false},{"date":"2024-06-30","value":-2490700000,"profit":false},{"date":"2025-06-30","value":-1837700000,"profit":false}] |
| EPS (Diluted) | (4.20) | (5.71) | (3.33) | (6.42) | (1.75) | [{"date":"2021-06-30","value":-420,"profit":false},{"date":"2022-06-30","value":-571,"profit":false},{"date":"2023-06-30","value":-333.32,"profit":false},{"date":"2024-06-30","value":-641.99,"profit":false},{"date":"2025-06-30","value":-175,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| IBIO | |
|---|---|
| Cash Ratio | 4.86 |
| Current Ratio | 9.04 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| IBIO | |
|---|---|
| ROA (LTM) | -36.99% |
| ROE (LTM) | -70.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| IBIO | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| IBIO | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 255.62 |
| P/B | 1.29 |
| Price/FCF | NM |
| EV/R | 76.61 |
| EV/Ebitda | NM |
| PEG | NM |
iBio, Inc. Common Stock (IBIO) share price today is $2.22
Yes, Indians can buy shares of iBio, Inc. Common Stock (IBIO) on Vested. To buy
Yes, you can purchase fractional shares of iBio, Inc. Common Stock (IBIO) via the Vested app. You can start investing in iBio, Inc. Common Stock (IBIO) with a minimum investment of $1.
You can invest in shares of iBio, Inc. Common Stock (IBIO) via Vested in three simple steps:
The 52-week high price of iBio, Inc. Common Stock (IBIO) is $6.89. The 52-week low price of iBio, Inc. Common Stock (IBIO) is $0.56.
The price-to-earnings (P/E) ratio of iBio, Inc. Common Stock (IBIO) is
The price-to-book (P/B) ratio of iBio, Inc. Common Stock (IBIO) is 1.29
The dividend yield of iBio, Inc. Common Stock (IBIO) is 0.00%
The market capitalization of iBio, Inc. Common Stock (IBIO) is $72.89M
The stock symbol (or ticker) of iBio, Inc. Common Stock is IBIO
Consider the share price of iBio, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether iBio, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in iBio, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the iBio, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of iBio, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that iBio, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
